Dysport vs. Letybo: Two Value-Priced Botox Alternatives, Compared (2026 Guide)

If you are looking for an effective neurotoxin that does not price like Botox, Dysport and Letybo are the two best-positioned options on the U.S. market in 2026. Both deliver real, FDA-approved softening of glabellar lines. Both routinely come in below Botox on a per-treatment basis. And both tend to hit visible onset faster than Botox does.

But despite the similar price and similar role, these are not the same product. Dysport has been on the U.S. cosmetic market since 2009 and is known for a slightly broader diffusion profile that suits broad areas like the forehead. Letybo, FDA-approved in February 2024 and already the top-selling toxin in South Korea, has a tighter spread better suited to smaller, more precise targets. This guide walks through the meaningful differences based on the FDA labels, the BLESS phase-3 trial program behind Letybo, and what we see day to day at our Chatsworth and Santa Barbara clinics.

What Dysport and Letybo Actually Are

Both are purified type A botulinum toxins. Both work by temporarily blocking acetylcholine release at the neuromuscular junction, relaxing targeted facial muscles and softening the dynamic wrinkles above them. The mechanism is identical; the formulation and manufacturing history are different.

• Dysport (abobotulinumtoxinA) — manufactured by Galderma, FDA-approved cosmetically for glabellar lines in April 2009. The molecule is a complex of roughly 500–900 kDa, with a higher proportion of free 150 kDa active toxin than Botox. That looser complex contributes to Dysport’s reputation for broader diffusion.
• Letybo (letibotulinumtoxinA-wlbg) — manufactured by Hugel America, FDA-approved cosmetically for glabellar lines in February 2024. Letybo is a roughly 900 kDa complex similar in structure to Botox, which is why its diffusion behavior runs tight and predictable. Notably, the BLESS phase-3 program reported no neutralizing antibody formation across the development cohort.

In short: same chemistry of action, different complex behavior. Dysport spreads a little more, Letybo stays put a little better.

Onset: When Will You See Results?

Both products come on quickly, which is part of why they are reasonable picks for patients who have been frustrated by Botox’s slightly slower kick-in.

• Dysport onset: Most patients see softening at 2–3 days, with peak effect around 10–14 days. Dysport is widely cited as one of the fastest-acting cosmetic toxins on the U.S. market.
• Letybo onset: The BLESS trials reported median onset of approximately 2–3 days (median around 2.8 days), with peak effect at roughly 14 days.

For practical purposes, these onset windows are essentially the same. If you are choosing between these two products, do not pick based on speed of onset — they are matched.

Duration: How Long Will Results Last?

Same story.

• Dysport: Typical glabellar duration is 3–4 months. The FDA label notes effects “may last up to 4 months” and re-treatment no more often than every 3 months.
• Letybo: Typical glabellar duration is also 3–4 months. The BLESS I, II, and III trials reported durable response in this same window.

Real-world duration is driven much more by your metabolism, dose adequacy, treatment area, and injection technique than by the brand on the vial. If duration is your single top priority, the longer-acting option to discuss with your injector is Daxxify, which is studied at six months median duration. Between Dysport and Letybo, the duration question is essentially a tie.

Dosing and Unit Conversion

This is the area where the two products differ most on paper — and where the math is most likely to confuse a first-time patient comparing price lists.

Per the FDA labels:

• Dysport for glabellar lines: 50 units total, divided across 5 injection sites (10 units each). Roughly 2.5–3 units of Dysport equal 1 unit of Botox.
• Letybo for glabellar lines: 20 units total, divided across 5 injection sites (4 units each). The dosing ratio against Botox is approximately 1:1.

So a Dysport patient and a Letybo patient leaving with the same clinical result will have received 50 units versus 20 units, respectively. Comparing per-unit prices between these two products is essentially meaningless. What matters is total per-treatment cost, which is the only meaningful comparison.

Diffusion and Precision

This is the single most important practical difference between Dysport and Letybo.

Dysport tends to diffuse — spread outward from the injection point — slightly more than its peers. That is well-suited to broad, flat treatment areas:

• Forehead, where you want even softening across a wide muscle with fewer injection points
• Patients who prefer fewer needle pricks per session
• Diffuse-pattern treatment goals where minor over-spread is helpful rather than risky

Letybo diffuses tightly, similar to Botox. That makes it well-suited to focal, precision-sensitive areas:

• Crow’s feet, where you do not want toxin drifting toward the zygomaticus and weakening your smile
• Lip flips and perioral work, where a millimeter of unwanted spread changes your mouth shape
• Bunny lines, chin dimpling, and other small targets where you want the toxin to stay exactly where it is placed

A skilled injector can use either product anywhere on the upper face by adjusting dilution and volume per site, but the underlying tendency is real — and it is the single biggest reason an experienced provider may recommend one over the other for your specific anatomy.

Cost: What You Will Actually Pay in 2026

This is the rare neurotoxin comparison where both products land in the same value tier.

• Dysport: roughly $4–$7 per unit. A standard glabellar treatment of 50 units lands around $250–$350.
• Letybo: roughly $9–$15 per unit. A standard glabellar treatment of 20 units lands around $200–$300.

Per-treatment, Letybo often comes in modestly cheaper, primarily because the smaller unit count works in patients’ favor at the cash register. Dysport’s lower-end per-unit pricing is more visible on a price list, but you are using more units, so the totals end up close. For a glabellar-only patient, Letybo may save you $30–$80 per treatment versus Dysport at most clinics.

Be careful comparing clinics that quote “per area” instead of “per unit” — per-area pricing can hide undertreatment. At Naya Wellness, we quote per unit so you always know exactly what you are paying for.

Side Effects and Safety

Both products carry essentially identical side effect profiles, because the mechanism of action is identical. In FDA-controlled trials, the most common adverse events for both were:

• Headache (3–11%)
• Injection-site reactions — bruising, redness, mild swelling (1–5%)
• Eyelid drooping (ptosis), typically less than 1% in trained hands
• Asymmetric brow position, usually correctable with a small touch-up at the two-week mark

Both products carry the FDA boxed warning regarding the theoretical possibility of distant toxin spread; at cosmetic facial doses, this has not been a clinically meaningful concern.

One specific point worth knowing about Letybo: the BLESS phase-3 program reported no neutralizing antibody formation across the development cohort. Neutralizing antibodies that reduce a toxin’s effectiveness are very rare with any cosmetic neurotoxin, but it is a clean signal for Letybo. Dysport’s antibody profile is also low but not zero across long-term use.

Who Is the Ideal Candidate for Each?

Dysport may be the better fit if:

• You are treating broad areas like the forehead
• You want the slightly faster-onset option (a few hours’ edge in some patients)
• You prefer a product with a longer U.S. track record
• You like the idea of fewer, more widely spaced injection points

Letybo may be the better fit if:

• You are treating smaller, focal areas — crow’s feet, lip flips, bunny lines, chin
• You want a tightly diffusing toxin that stays where it is placed
• You are price-sensitive and want the lowest typical per-treatment cost on the menu
• You are interested in the clean antibody signal from the BLESS phase-3 program

Can You Switch Between Dysport and Letybo?

Yes. Many patients try one and switch to the other depending on what they are treating. A few practical notes:

• Always tell your new injector exactly which product you previously had, the dose, and roughly when. Because the unit counts are very different (50 vs. 20), this conversion matters.
• You cannot stack the two in the same treatment area in the same session.
• Switching products does not require any wash-out period — both work on the same neurotransmitter pathway.
• If you are switching from Dysport to Letybo, expect a slightly tighter pattern of effect; if you are going the other direction, expect a slightly broader pattern. Most patients find both acceptable; some have a clear preference.